Helping You Build Wealth With Honest Research
Since 1996. Try Now

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Indian share markets open firm
Tue, 30 Oct 09:30 am

Asian stock markets have opened the day on a mixed note with stock markets in Hong Kong (down 0.5%) and Japan (down 0.4%) leading the losses in the region. However, markets in Taiwan (up 1%) and Malaysia (up 0.2%) are trading firm. The Indian share market indices have opened the day with marginal gains. Stocks in the realty, IT and banking space are leading the gains. However, consumer durables and capital goods stocks are trading weak.

The Sensex today is up by around 15 points (0.1%), while the NSE-Nifty is up by around 5 points (0.1%). Mid and small cap stocks are also trading in the green with the BSE Mid Cap and BSE Small Cap indices up by around 0.1% and 0.3% respectively. The rupee is trading at Rs 54.01 to the US dollar.

Textile stocks have opened the day on a mixed note with Raymond and Arvind Ltd trading firm. However, Grasim Industries and Vardhman Textiles are facing selling pressure. Aditya Birla Group company Grasim Industries has announced its financial results for the quarter ended September 2012 (2QFY13). During the quarter, the company's standalone net sales stood at Rs 13,344.8 m, higher by 9.6% on a year-on-year (YoY) basis. The growth in the topline was mainly driven by about 8% YoY increase in volume sales. Operating profits declined by 5.3% YoY to Rs 2,898 m due to higher input costs. Interest expenses and tax outgo declined by 27.1% YoY and 38.1% YoY. This helped net profits to rise by 11% YoY to Rs 3,827.3 m. Net margins improved marginally from 28.3% in 2QFY12 to 28.7% in 2QFY13.

Indian pharma stocks have opened the day on a firm note with Torrent Pharma, Glenmark Pharma and Dishman Pharma leading the gains. As per a leading financial daily, Piramal Healthcare has tied up with Japanese firm Fujifilm Diosynth Biotechnologies for a contract manufacturing deal. The deal would be aimed at developing antibody drug conjugates (ADC). The partnership between the two firms is expected to cover over 150 bio-pharmaceuticals and more than 300 batches of ADC which would cover over 30 different new chemical entities. It must be noted that ADC is a field in bio-pharma that focuses on targeted therapy, specifically in the treatment of cancer. While in traditional chemotherapy even good cells get killed in the process, in targeted therapy, specific cancer-causing cells are targeted.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Indian share markets open firm". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Agora Research Private Limited.

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Agora Research Private Limited (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.